ES / EN
- July 15, 2025 -
No Result
View All Result
OnCubaNews
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
OnCubaNews
ES / EN
Home Coronavirus

Cuba negotiates with other countries to develop phase 3 of Soberana 02 vaccine

Negotiations are progressing to develop Phase 3 of the Soberana 02 clinical trial in other countries, due to the low prevalence of COVID-19 in the Cuban population.

by
  • EFE
    EFE,
  • EFE
    EFE
December 30, 2020
in Coronavirus, Cuba
0
Phase 2 of Soberana 02’s clinical trials will involve nearly a thousand volunteers starting
January. EFE/Archive.

Phase 2 of Soberana 02’s clinical trials will involve nearly a thousand volunteers starting January. EFE/Archive.

Cuba is negotiating to develop in other countries the last phase of trials of one of its four vaccine projects against SARS-CoV-2, since the “low prevalence” of the virus on the island prevents these tests from being carried out effectively.

“Negotiations are progressing to develop Phase 3 of the Soberana 02 clinical trial in other countries, due to the low prevalence of COVID-19 in the Cuban population,” indicates a note from the Presidency released this Tuesday in state media.

The candidate referred to in the negotiations is Soberana 02, developed by the Finlay Vaccine Institute (IFV) and which has just entered phase 2 of clinical trials. This stage will involve nearly a thousand volunteers as of January, who will be administered the preparation in “different formulations,” said the director general of the IFV, Vicente Vérez, quoted in the note.

Second phase of Cuban Soberana 02 vaccine candidate’s clinical trials approved

This figure varies with respect to those released in previous days, when Vérez declared to the state newspaper Granma that phase 2 would involve about a hundred people, which would increase to between 300 and 600 in phase II-B.

According to the scientist, said candidate “has shown an early immune response (at 14 days), which makes it possible to go on to phase 2 of the clinical trial more quickly.”

Related Posts

Sandra Sotolongo, co-director of the “inSurGENTES” project, during an activity in the vegetable garden. Photo: Courtesy.

Insurgents, an open-air revolution

July 10, 2025
Private business on Infanta and 23rd Streets, in Vedado, Havana. Photo: AMD.

MSMEs barely growing and their slowdown hinders competition and economic dynamism

July 9, 2025
Entrance to San Juan Park, located east of Santiago.

San Juan Hill: heritage in the attic?

July 6, 2025
Headquarters of the Matanzas People’s Court, where the trial was held. Photo: Matanzas People’s Court/Facebook.

Prosecutor’s Office requests up to 9 years in prison for synthetic drug trafficking in Matanzas

June 30, 2025

Once this second phase is concluded and evaluated, phase 3 will begin, in which some 150,000 people will participate in Havana―the Cuban province with the highest rates of contagion in recent weeks―and a number yet to be determined if the negotiations are finally finalized, to test it in other countries as well.

Sovereign 02 combines the virus antigen and tetanus toxoid, and also uses aluminum hydroxide to stimulate the immune system response.

Vérez “ratified the country’s ability to immunize the Cuban population against the SARS-CoV-2 virus in the first half of 2021,” adds the note, released on the occasion of a visit to the Finlay Institute on Monday by Cuban President Miguel Díaz-Canel.

Several people in protective suits against the coronavirus check the work material inside the red zone at the Jardines del Rey international airport in Cayo Coco in Cuba. EFE/Ernesto Mastrascusa/Archive.

The president, who was informed about the progress of Soberana 01 and Soberana 02, praised the work of the group of researchers, mostly women, and highlighted that except for Cuba “no third world country has a COVID-19 vaccine in the clinical trial,” says the official statement.

The IFV is also developing the candidate Soberana 01, which is about to conclude phase 1 of clinical trials and, according to the director of the center, “has also shown safety and a very good immune response, but it is slower due to the time it takes between one dose and another.”

In addition to these two projects of the Finlay Institute, the Center for Genetic Engineering and Biotechnology (CIGB) of the Caribbean country is working on two other candidates: Abdala (intramuscular) and Mambisa (intranasal), which will begin clinical trials in which each will be tested in two phases.

Cuba, which to date has a total of 11,601 cases of coronavirus and 143 deaths, has a recognized biotechnology and pharmaceutical industry that currently produces eight vaccines against diseases such as meningitis, lung cancer (therapeutic) and solid tumors, among others.

Most of the Caribbean country entered a “new normal” stage in October that includes the operation of activities and services at full capacity, although some measures such as the mandatory use of a mask in public places and physical distancing are maintained.

The authorities announced this week new measures to curb a rising wave of infections attributed to the reopening of international airports in mid-October, and a month later in the case of Havana.

  • EFE
    EFE,
  • EFE
    EFE
Tags: coronavirus in CubaCuban vaccine against COVID-19
Previous Post

ETECSA reports services to be affected at end of year

Next Post

Cuba reports two deaths from COVID-19 and 86 new cases with the disease

EFE

EFE

EFE

EFE

Next Post
Photo: Otmaro Rodríguez/Archive.

Cuba reports two deaths from COVID-19 and 86 new cases with the disease

Cuban Foreign Minister Bruno Rodríguez Parrilla gives a press conference in Havana. Photo:
Otmaro Rodríguez/Archive.

Cuba could be included in list of countries that sponsor terrorism, Bruno Rodríguez denounces

Photo: Otmaro Rodríguez.

2020: the year of the pandemic

Leave a Reply Cancel reply

The conversation here is moderated according to OnCuba News discussion guidelines. Please read the Comment Policy before joining the discussion.

Your email address will not be published. Required fields are marked *

Most Read

  • OFAC.S. Department of the Treasury. Photo: Marita Pérez Díaz.

    OFAC fines U.S. company over $600,000 for shipping to Cuba

    37 shares
    Share 15 Tweet 9
  • Staying silent in Cuba: a choice?

    13 shares
    Share 5 Tweet 3
  • MSMEs barely growing and their slowdown hinders competition and economic dynamism

    12 shares
    Share 5 Tweet 3
  • Los Palacios, land of Cuban rice harvested by Vietnamese

    19 shares
    Share 8 Tweet 5
  • Trump reinstates hard-line Cuba embargo as Havana condemns US measure as “criminal”

    37 shares
    Share 15 Tweet 9

Most Commented

  • Photo: Kaloian.

    Private sector and tourism in Cuba. Why not?

    12 shares
    Share 5 Tweet 3
  • About us
  • Work with OnCuba
  • Terms of use
  • Privacy Policy
  • Moderation policy for comments
  • Contact us
  • Advertisement offers

OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

No Result
View All Result
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors

OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}